Table 2.

Meta-analysis on the effect of VSE triple therapy on different reported outcomes using a random-effect model

Meta-analysis					Heterogeneity
Outcomes	N. of studies	N. of participants	ES (95% CI)	P value effect	Q statistic	I-squared (%)	P value
Survival	3	869	2.082 (0.638–6.796)	0.225	9.310	78.517	0.010
ROSC	3	869	2.281 (1.304–3.989)	0.004	5.454	63.328	0.065
MAP during CPR	2	368	1.069 (0.851–1.288)	< 0.001	0.080	0.000	0.777
MAP 15–20 min after CPR	2	368	0.831 (0.553–1.110)	< 0.001	0.503	33.446	0.220
Ventilator free days	3	869	0.201 (− 0.677 to 1.079)	0.838	44.108	95.466	< 0.001
Renal failure free days	2	368	0.590 (0.312–0.869)	< 0.001	0.043	0.0001	0.836
Insulin requirement	3	869	1.711 (1.324–2.212)	< 0.001	1.060	0.0001	0.589
Coagulation failure free days	2	368	0.403 (0.128–0.679)	0.004	0.271	0.0001	0.603

N number, ES effect size, CI confidence interval, ROSC return of spontaneous circulation, MAP mean arterial pressure, CPR cardiopulmonary resuscitation